| ezetimibe / Generic mfg. |
ChiCTR-ICR-15007290: Correlation between gut microbiota metabolite TMAO and sevrity of coronary artery disease and effects of ezetimibe on plasma TMAO levels |
|
|
| Recruiting | N/A | 90 | | the patients were treated by simvastatin 20mg/d ;the patients were treated by ezetimibe 10mg/d ;the patients were treated by ezetimibe 10mg/d and simvastatin 20mg/d | Xin Hua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine; Xin Hua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, 50,000 yuan raised | coronary heart atherosclerotic disease | | | | |
INTENSITY-HIGH, NCT03355027: Investigating the Lowest Threshold of Vascular Benefits From LDL Cholesterol Lowering in Patients With Stable CV Disease |
|
|
| Active, not recruiting | N/A | 60 | Europe | Alirocumab 150 MG/ML, Praluent, Ezetimibe 10Mg Tablet, Ezetrol, Atorvastatin 40Mg Tablet, Atorvastatin 80Mg Tablet, Rosuvastatin 20Mg Tablet, Crestor, Rosuvastatin 40Mg Tablet, Simvastatin 80mg | Cambridge University Hospitals NHS Foundation Trust, University of Cambridge | Atherosclerosis, Cardiovascular Diseases | 09/19 | 11/23 | | |
ChiCTR1800016885: Study for the efficacy and safety of Xue-Zhi-Kang combined with ezetimibe in the treatment of non-dialysis chronic renal disease patients |
|
|
| Not yet recruiting | N/A | 300 | | Xuezhikang 0.6g bid ;Xuezhikang 0.6g bid and Ezetimibe 10mg qd ;Atorvastatin 20mg qn | Second Affiliated Hospital of Chongqing Medical University; Second Affiliated Hospital of Chongqing Medical University, Dyslipidemia and atherosclerosis research foundation of xinxin foundation | non-dialysis chronic kidney diseases | | | | |
ChiCTR1900025233: Effects of evolocumab on plaque stability and clinical prognosis in patients with atherosclerotic cardiovascular disease |
|
|
| Not yet recruiting | N/A | 100 | | Statins + ezetimibe ;Statins + ezetimibe+evolocumab | Hebei General Hospital; Hebei General Hospital, Scientific research fund from hebei science and technology department | atherosclerotic cardiovascular disease | | | | |
ChiCTR2100044503: Real-world study: The effect of statin combined with evolocumab on blood lipids and thrombus in patients with ultra-high-risk ASCVD |
|
|
| Recruiting | N/A | 60 | | statin combined with eloyuumab ;statin combined with ezetimibe | Xiangya Hospital, Central South University; Xiangya Hospital, Central South University, Xinxin Cardiovascular Health Foundation-Advanced Fund 2020 | atherosclerotic cardiovascular disease (ASCVD) | | | | |
ChiCTR2100045091: Real-world study of the efficacy, safety, and cardiovascular benefits of initial combined lipid-lowering therapy in outpatients with very high-risk ASCVD |
|
|
| Recruiting | N/A | 60 | | Atorvastatin (Sumaitone: 20mg Po QN) combined with iluzumab injection (Rebenon: 420 mg sc once a month) ;Atorvastatin (sumetone: 20mg po QN) combined with ezetimibe (episol: 10 mg po QD) | Xiangya Hospital, Central South University; Xiangya Hospital, Central South University, Xinxin Cardiovascular Health Foundation-Advanced Fund 2020 | atherosclerotic cardiovascular disease (ASCVD) | | | | |
ChiCTR2200057789: Randomized controlled clinical study of medium-intensity statins combined with ezetimibe and high-intensity statins for lipid-lowering treatment of acute ischemic cerebrovascular disease |
|
|
| Not yet recruiting | N/A | 150 | | moderate intensity statins with ezetimibe ;high intensity statins | The Fifth Affiliated Hospital of Sun Yat-sen University; The Fifth Affiliated Hospital of Sun Yat-sen University, None | Acute ischemic stroke/transient ischemic attack | | | | |
LDL-ALERT, NCT05088759: Randomized Controlled Trial of Alert-Based Computerized Decision Support for Optimizing Low-Density Lipoprotein Management |
|
|
| Active, not recruiting | N/A | 400 | US | Alert | Brigham and Women's Hospital | Hyperlipemia, Mixed, ASCVD | 12/22 | 09/24 | | |
ChiCTR2200063395: Optical coherence tomography (OCT) study: the sub-study of a randomized controlled trail of intensive lipid-lowering therapy to improve the prognosis of patients with ACS and the establishment of a residual risk assessment model for blood lipids |
|
|
| Not yet recruiting | N/A | 36 | | Intensive Lipid-Lowering Therapy(PCSK9 Monoclonal Antibodies+statins ±ezetimibe) ;Conventional Lipid-Lowering Therapy(statins ±ezetimibe) | Cardiometabolic Center, National Center for Cardiovascular Diseases, Fuwai Hospital, Chinese Academy of Medical Science & Peking Union Medical College; Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, 2021-2025CAMS Innovation Fund for Medical Sciences (CIFMS) | Acute coronary syndrome | | | | |
SIRIUS, NCT05974345: In Silico Study Assessing the Impact of Inclisiran on Major Adverse Cardiovascular Events in Patients With Established Cardiovascular Disease |
|
|
| Completed | N/A | 204691 | Europe | Inclisiran sodium, Placebo, Ezetimibe, Evolocumab | Novartis Pharmaceuticals | Atherosclerotic Cardiovascular Disease | 12/23 | 12/23 | | |
| Recruiting | N/A | 500 | RoW | Ezetimibe 10mg | Cairo University, Aswan Heart Centre | Acute Myocardial Infarction, Dyslipidemias | 12/23 | 04/24 | | |
PERI-DYS, NCT03110432: Prospective German Very High Cardiovascular Risk Patients Dyslipidemia Treatment Indication Registry |
|
|
| Active, not recruiting | N/A | 1713 | Europe | PCSK9 Inhibitor [EPC], Repatha, Praluent, Standard lipid lowering therapy, Statins, ezetimibe, nicotinic acid, fibrates, cholestagel, omega-3 fatty acids | GWT-TUD GmbH | Dyslipoproteinemias | 03/24 | 06/24 | | |
NCT06314919: A Study to Evaluate the Efficacy and Safety of Fixed-Dose Combination of Pitavastatin/Ezetimib |
|
|
| Recruiting | N/A | 8606 | RoW | | Boryung Pharmaceutical Co., Ltd | Primary Hypercholesterolemia, Mixed Dyslipidemia | 03/26 | 03/26 | | |
| Recruiting | N/A | 200 | RoW | Combined Lipid-lowering Therapy, invasive coronary angiography, coronary artery commputed tomography, OCT, CAVI index | Samara Regional Cardiology Dispensary, Samara State Medical University | Dyslipidemias | 05/24 | 05/24 | | |
ChiCTR2300071501: Effects and mechanism study of PCSK9 inhibitor on cardiac function in patients with ultra-high-risk coronary atherosclerosis: A Study Protocol for a Randomized controlled protocol |
|
|
| Recruiting | N/A | 266 | | application of PCSK9 inhibitors ;statins alone or in combination with ezetimibe | the Second Hospital of Tianjin Medical University; the Second Hospital of Tianjin Medical University, mentor funds | Atherosclerotic cardiovascular disease | | | | |
NCT03648788: A Post-marketing Surveillance to Assess Safety and Efficacy of Rosuvatatin/Ezetimibe |
|
|
| Not yet recruiting | N/A | 600 | NA | NA (Observation study) | IlDong Pharmaceutical Co Ltd | Mixed Dyslipidemia | 06/24 | 08/24 | | |
| Recruiting | N/A | 180 | RoW | Genetic Testing, Motivational Counseling, Motivational Interviewing, Lipid analysis, Consultation with a cardiologist-lipidologist (correction of therapy, lifestyle, diet), Visit 1, Visit 2, Visit 3, Visit 4 | National Medical Research Center for Therapy and Preventive Medicine, Moscow State University of Medicine and Dentistry | Hypercholesterolemia, Familial, Hypercholesterolemia, Familial, 1, Hypercholesterolemia, Familial, 2, Hypercholesterolemia, Familial, 3, Hypercholesterolemia, Familial, 4, Hypercholesterolemia, Familial, 4, Autosomal Recessive, Familial Hypercholesterolemia With Hyperlipemia, Hypercholesterolemia, Autosomal Dominant, Type B, Hypercholesterolemia, Autosomal Dominant, Hypercholesterolemia, Autosomal Dominant, 3, Apolipoprotein B-100, Familial Defective, Genetic Testing, Motivational Interviewing, Therapeutic Adherence, Therapeutic Adherence and Compliance, Treatment Adherence, Medication Adherence, Treatment Adherence and Compliance, Patient Adherence, Compliance, Patient Compliance, Familial Hypercholesterolemia, Familial Hypercholesterolemia - Heterozygous, Adherence, Patient, Adherence, Medication, Adherence | 09/24 | 03/25 | | |
NCT05705804: Effects of Pitavastatin or Combination of Pitavastatin and Ezetimibe on Glucose Metabolism Compared to AtoRvastatin in atheroscLerotic Cardiovascular Disease Patients With Metabolic Syndrome: The EZ-PEARL Randomized Trial |
|
|
| Recruiting | N/A | 250 | RoW | Pitavastatin, Pitavastatin plus Ezetemibe, Atorvastatin | Yonsei University | Dyslipidemias, Atherosclerotic Cardiovascular Disease | 02/25 | 04/25 | | |
MILOS, NCT04579367: Treatment With Bempedoic Acid and/or Its Fixed-dose Combination With Ezetimibe in Primary Hypercholesterolemia or Mixed Dyslipidemia |
|
|
| Recruiting | N/A | 5000 | Europe | Bempedoic acid and/or its fixed-dose combination with ezetimibe | Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company | Hypercholesterolemia, Mixed Dyslipidemia | 09/25 | 09/25 | | |
NCT06096909: Early Initiation of Tafolecimab for Patients With Acute Coronary Syndromeundergoing Percutaneous Coronary Intervention in Chinese Population |
|
|
| Not yet recruiting | N/A | 3684 | NA | Tafolecimab, Cholesterol Absorption Inhibitor, Statin | China National Center for Cardiovascular Diseases, Innovent Biologics, Inc. | Acute Coronary Syndrome, Non ST Segment Elevation Acute Coronary Syndrome | 11/25 | 11/27 | | |
JaZ, NCT05587621: Intensive Lipid-lowering in Patients With STEMI and NSTEMI (Germany on Target) |
|
|
| Not yet recruiting | N/A | 300 | Europe | statins, ezetimibe, bempedoic acid, evolocumab, alirocumab, inclisiran, dietary advice | Jena University Hospital | ST Elevation Myocardial Infarction, Non-ST Elevation Myocardial Infarction, LDL-cholesterol | 04/26 | 12/26 | | |
MILOS-Spain, NCT05798390: Treatment With Bempedoic Acid And/Or Its Fixed-dose Combination With Ezetimibe in Routine Clinical Practice in Patients With Primary Hypercholesterolemia Or Mixed Dyslipidemia |
|
|
| Withdrawn | N/A | 1100 | NA | Bempedoic acid and/or its fixed dose combination with ezetimibe | Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company | Primary Hypercholesterolemia, Mixed Dyslipidemia | 04/26 | 04/26 | | |
NCT05765370: LDL Cholesterol TARGETs in OLDer Patients (Age≥75 Years) With ASCVD (TARGET OLD) |
|
|
| Recruiting | N/A | 4200 | RoW | Achieving a Target LDL-C level of 25mg/dL≤ LDL-C<70mg/dL, Achieving a Target LDL-C level of 70mg/dL≤ LDL-C<100mg/dL | China National Center for Cardiovascular Diseases | Atherosclerotic Cardiovascular Disease, Older Patients, LDL Cholesterol | 09/26 | 12/26 | | |
VICTORION REAL, NCT05399992: Study Evaluating Effectiveness and Adherence of Inclisiran Plus Standard of Care (SoC) Lipid-lowering Therapy Compared to SoC in ASCVD |
|
|
| Recruiting | N/A | 2100 | Europe, RoW | Inclisiran | Novartis Pharmaceuticals | Primary Hypercholesterolemia, Mixed Dyslipidemia | 05/27 | 05/27 | | |
NCT05782777: Effect of High-intensity Statin With Ezetimibe COmbination theRapy Versus High-intensity sTatin Monotherapy After Percutaneous Coronary Intervention With Drug-eluting Stents; the ESCORT Trial |
|
|
| Recruiting | N/A | 4310 | RoW | ezetimibe/high-intensity statin combination therapy (ezetimibe 10mg plus atoravastatin 40mg), high-intensity statin monotherapy (atoravastatin 40mg) | Yonsei University | Coronary Artery Disease Requiring Coronary Revascularization With Newer Generation DES Implantation | 12/27 | 12/27 | | |
| Recruiting | N/A | 450 | US | Medical/Behavioral therapy, Standard of Care, Registry | Emory University | Coronary Artery Disease | 12/28 | 12/28 | | |
